Comprehensive And Streamlined Genomic Signature Assessment With VARIANTPlex™ Solid Tumor Solutions

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

Capturing the full complexity of tumor biology requires more than isolated biomarker testing. Advances in next-generation sequencing now enable simultaneous assessment of key genomic signatures—homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI)—revealing how these interconnected markers shape tumor behavior and therapeutic response. A unified, modular approach streamlines this process, reducing sample consumption while improving efficiency and data depth. Anchored multiplex PCR (AMP) chemistry supports flexible panel design and robust variant detection, while integrated analysis workflows deliver highly concordant results across multiple signature types. By consolidating genomic profiling into a single workflow, laboratories can generate more complete insights, optimize resources, and better support precision oncology research.

Discover how a modular strategy can simplify complex genomic assessments while expanding discovery potential.